Literature DB >> 15209651

A population-based osteoporosis screening program: who does not participate, and what are the consequences?

Diana S M Buist1, Andrea Z LaCroix, Susan K Brenneman, Thomas Abbott.   

Abstract

OBJECTIVES: To describe differences in osteoporosis risk factors and rates of fracture and antiresorptive therapy use in women who did and did not participate in an osteoporosis screening program.
SETTING: Group Health Cooperative, a health maintenance organization in western Washington state. PARTICIPANTS: A total of 9,268 women (aged 60-80) who were not using any antiresorptive therapy were invited to participate in an osteoporosis screening program. This study compares the 35% who participated with the 65% who did not.
DESIGN: This observational cohort study of women invited to participate in a randomized, controlled trial of an osteoporosis screening program provided all participants with personalized feedback on their risk of osteoporosis. Some participants also received bone density testing. Automated administrative data were used to examine differences between participants and nonparticipants in fracture outcomes and medication initiation before and after invitation.
RESULTS: Baseline fracture rates did not differ between participants and nonparticipants. After age adjustment, nonparticipants had a higher hip fracture rate (14.1 vs 8.3 per 1,000) and a lower rate of initiating any antiresorptive therapy (10.3 vs 17.9 per 100) than participants after an average of 28 to 29 months of follow-up.
CONCLUSION: Participants had reduced hip fracture rates and increased initiation of antiresorptive therapy compared with nonparticipants. It was not possible to determine whether participating in the screening program, unmeasured confounding, or selection bias accounted for differences in hip fracture or therapy initiation rates. These results suggest that women who do not participate in osteoporosis screening should be pursued to identify individuals who could benefit from primary and secondary osteoporosis prevention.

Entities:  

Mesh:

Year:  2004        PMID: 15209651     DOI: 10.1111/j.1532-5415.2004.52311.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  20 in total

1.  Frequent antibiotic use and second breast cancer events.

Authors:  Heidi S Wirtz; Diana S M Buist; Julie R Gralow; William E Barlow; Shelly Gray; Jessica Chubak; Onchee Yu; Erin J A Bowles; Monica Fujii; Denise M Boudreau
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-05       Impact factor: 4.254

2.  Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk.

Authors:  R J Barr; A Stewart; D J Torgerson; D M Reid
Journal:  Osteoporos Int       Date:  2009-06-30       Impact factor: 4.507

3.  Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study.

Authors:  Gregory S Calip; Onchee Yu; Joann G Elmore; Denise M Boudreau
Journal:  Cancer Causes Control       Date:  2016-04-06       Impact factor: 2.506

4.  Statin use and breast cancer risk in a large population-based setting.

Authors:  Denise M Boudreau; Onchee Yu; Diana L Miglioretti; Diana S M Buist; Susan R Heckbert; Janet R Daling
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-03       Impact factor: 4.254

5.  Evidence for Detection Bias by Medication Use in a Cohort Study of Breast Cancer Survivors.

Authors:  Heidi S Wirtz; Gregory S Calip; Diana S M Buist; Julie R Gralow; William E Barlow; Shelly Gray; Denise M Boudreau
Journal:  Am J Epidemiol       Date:  2017-04-15       Impact factor: 4.897

6.  Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer.

Authors:  Denise M Boudreau; Onchee Yu; Jessica Chubak; Heidi S Wirtz; Erin J Aiello Bowles; Monica Fujii; Diana S M Buist
Journal:  Breast Cancer Res Treat       Date:  2014-02-21       Impact factor: 4.872

7.  Cardiovascular medication use and risk for colorectal cancer.

Authors:  Denise M Boudreau; Elizabeth Koehler; Stephen J Rulyak; Sebastien Haneuse; Robert Harrison; Margaret T Mandelson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-10-28       Impact factor: 4.254

8.  Endocrine therapy initiation from 2001 to 2008 varies by age at breast cancer diagnosis and tumor size.

Authors:  Erin J Aiello Bowles; Diana S M Buist; Jessica Chubak; Onchee Yu; Jeanene Johnson; Janet Chestnut; Denise M Boudreau
Journal:  J Oncol Pract       Date:  2012-02-21       Impact factor: 3.840

9.  Statin use and female reproductive organ cancer risk in a large population-based setting.

Authors:  Onchee Yu; Denise M Boudreau; Diana S M Buist; Diana L Miglioretti
Journal:  Cancer Causes Control       Date:  2008-11-30       Impact factor: 2.506

10.  Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment.

Authors:  Gregory S Calip; Denise M Boudreau; Elizabeth T Loggers
Journal:  Breast Cancer Res Treat       Date:  2013-01-29       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.